New York, United States — The weight-loss drug market in the U.S. entered a new phase this week as Novo Nordisk officially launched its once-daily Wegovy pill, giving patients a needle-free alternative in a space long dominated by injectable treatments.
The pill, approved last month by the Food and Drug Administration, is now available nationwide, with starter doses priced as low as $149 per month for self-paying patients. The move positions Novo Nordisk to regain momentum after losing market share to U.S. rival Eli Lilly during the past year.
Pricing structure targets cash-paying customers
Novo Nordisk is launching the Wegovy pill in 1.5 mg and 4 mg doses at $149 per month for self-pay patients. According to the company, higher doses — 9 mg and a long-term 25 mg dose — will be priced at $299 per month, while the 4 mg dose will increase to $199 starting April 15.
The strategy reflects a growing shift in the weight-loss market toward direct-to-consumer pricing, as many insurers continue to limit or deny coverage for obesity medications.
“The success of this pill will largely depend on attracting people who are paying out of pocket,” analysts say, noting that insurance coverage remains inconsistent across the U.S.
By comparison, list prices for injectable weight-loss drugs often exceed $1,000 per month, though both major manufacturers have introduced cash-pay discounts to stay competitive.
A familiar ingredient in a new form
The Wegovy pill contains semaglutide, the same active ingredient used in Novo Nordisk’s blockbuster injectable drugs Wegovy and Ozempic. Semaglutide is also used in the company’s oral diabetes medication Rybelsus, though at different dosing levels.
The 1.5 mg pill serves as a starter dose, allowing patients to gradually adjust before moving to higher strengths. Novo said remaining doses would be available to patients by the end of the week.
“The pill offers flexibility and convenience for patients who are uncomfortable with injections,” the company said, emphasizing daily oral dosing as a key selling point.
Pharmacies and telehealth platforms expand access
Novo Nordisk confirmed that the Wegovy pill will be available through major U.S. pharmacies including CVS and Costco, as well as several telehealth providers.
Those providers include Ro, LifeMD, WeightWatchers, GoodRx, and Novo’s own NovoCare Pharmacy. The multi-channel rollout is designed to make access easier for consumers who may not have traditional physician coverage for weight-loss care.
Market reaction was immediate, with Novo Nordisk shares rising about 3%, while Eli Lilly shares dipped slightly in premarket U.S. trading.
Competition intensifies with Eli Lilly waiting in the wings
Eli Lilly is developing its own oral obesity treatment and has said it expects a regulatory decision by March. The company has already stated it plans to cap higher doses of its pill at $399 per month for repeat cash buyers if approved.
Lilly’s injectable drug Zepbound has led Novo’s Wegovy in weekly U.S. prescriptions for much of the past year, raising the stakes for Novo’s latest launch.
“This is a pivotal moment for Novo as it tries to win back patients with a more convenient option,” industry analysts noted.
Supply confidence after earlier shortages
Novo Nordisk faced repeated supply shortages following the initial U.S. launch of its Wegovy injection. This time, the company says it has taken steps to avoid similar disruptions.
“We’ve built up inventory for the pill well in advance,” Novo said, adding that it is confident it can meet expected demand.
The pill is also under review by international regulators, with a decision expected in the UK by the end of the year.
What this means for patients
For many Americans struggling with weight management, the Wegovy pill offers a more affordable, needle-free entry point into prescription weight-loss treatment. However, experts caution that cost, long-term adherence, and insurance access will continue to shape who ultimately benefits.
As competition heats up and more oral options approach approval, the U.S. weight-loss drug market appears poised for rapid change in the months ahead.
Would you consider a daily weight-loss pill instead of injections? Share your thoughts in the comments below.
